STCube

Precision-Driven

Immuno-Oncology:

Targeting Novel Immune Checkpoints to Unlock Anti-Cancer Immunity

STCube is dedicated to developing

precision-driven immunotherapies,

bringing new hope to more cancer patients.

STCube, a Company
Developing First-in-Class
Immunotherapies
for Cancer

STCube is developing an immunotherapy that targets BTN1A1, a novel immune checkpoint for cancer treatment. We conduct research, development, and clinical trials in collaboration with leading domestic and international research institutions and establish strategic partnerships with multinational pharmaceutical companies to drive the successful development of new drugs.

Nelmastobart

World's First Anti-BTN1A1 Immune Checkpoint Inhibitor

NELMASTOBART 01

Clear Mechanism
of Action

BTN1A1 is expressed in mutually exclusive fashion with PD-L1 and serves as an immuno-oncology target with high expression rates in chemo-refractory and resistant cancer cells.
NELMASTOBART 02

Excellent Safety

One of the biggest challenges in cancer treatment is toxicity. Nelmastobart has been shown to have the highest level of safety and tolerability, even when administered for extended periods.
NELMASTOBART 03

Remarkable Anticancer Effect

Nelmastobart demonstrates a remarkable therapeutic response in cancers with limited treatment options. It offers a new therapeutic avenue for patients with treatment resistant/refractory or recurrent cancers.

Our Value

We seek to meet
the unmet needs in
cancer treatment
through innovative
therapies.

World-Class Research
in BTN1A1

Successful Completion of
Phase 1 Clinical Trial,
Confirming the Safety and
Efficacy of Nelmastobart

Securing Global Networks
with Top Institutions,
Including the MD Anderson
Cancer Center

Targeted Efforts toward
Clinical Success through
Precision-Medicine Based,
Biomarker-Driven Trials

Press

The Latest Updates from STCube

에스티큐브, 비소세포폐암 임상 2상 중간결과 발표…환자등록 73% 달성

에스티큐브, 비소세포폐암 임상 2상 중간결과 발표…환자등록 73% 달성- 목표 환자 62명 중 45명 등록…ORR 25.7%, DCR 88.6%로 초기 유효성 신호 확인- EGFR..

에스티큐브, ESMO서 넬마스토바트 3개 개발축 공개…병용 확장 전략 발표

에스티큐브, ESMO서 넬마스토바트 3개 개발축 공개…병용 확장 전략 발표■ 대장암, 비소세포폐암 임상 개발 및 EGFR 변이 비소세포폐암 오시머티닙 병용 전임상 연구 발표 에스티..

[KBR] Nelmastobart could pair with osimertinib after clean EGFR safety..

[팍스경제TV] 에스티큐브, '넬마스토바트' 비소세포폐암의 새로운 치료 대안 기대감...'병용 안전성 강조'

에스티큐브, 비소세포폐암 2상서 강력한 초기 효능 신호…ORR 26%, DCR 87%

에스티큐브, 비소세포폐암 2상서 강력한 초기 효능 신호…ORR 26%, DCR 87% - 사전 선별 환자 61%에서 BTN1A1 고발현…목표 환자 62명 중 34명 치료, 초기 ..

[약업신문] 에스티큐브 유승한 미국대표 “EGFR 변이 폐암 2상 효능 첫 공개…ORR 37.5%·오시머티닙 병용 추진”